Literature DB >> 25157386

Experimental Ebola drugs enter the limelight.

Asher Mullard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25157386     DOI: 10.1016/s0140-6736(14)61371-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

Review 2.  Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Authors:  Thomas P Monath; Stephen J Seligman; James S Robertson; Bruno Guy; Edward B Hayes; Richard C Condit; Jean Louis Excler; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2014-10-27       Impact factor: 3.641

Review 3.  Ebolavirus and Haemorrhagic Syndrome.

Authors:  Gerald A Matua; Dirk M Van der Wal; Rozzano C Locsin
Journal:  Sultan Qaboos Univ Med J       Date:  2015-05-28

Review 4.  Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases.

Authors:  Antonello Pessi
Journal:  J Pept Sci       Date:  2014-10-20       Impact factor: 1.905

Review 5.  Ebola hemorrhagic fever outbreaks: strategies for effective epidemic management, containment and control.

Authors:  Gerald Amandu Matua; Dirk Mostert Van der Wal; Rozzano C Locsin
Journal:  Braz J Infect Dis       Date:  2015-04-17       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.